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Key Points 
Question: Do easily-obtained hemodynamic metrics predict outcomes in patients with COPD 
and cardiovascular disease or high risk for cardiovascular events? 
 
Findings: In a randomized controlled trial, all-cause mortality increased in relation to high or 
low systolic or diastolic blood pressure. Higher heart rates and pulse pressures were linearly-
related to increases in all-cause mortality. 
 
Meaning: In COPD patients at risk for cardiovascular disease, unusual hemodynamic values 
portend a worse outcome and may warrant increased clinical vigilance.  
Abstract 
Importance: Cardiovascular disease is the leading cause of death in patients with chronic 
obstructive pulmonary disease (COPD).  While general associations between high blood pressure 
(BP) and cardiovascular risk are well-established, their prognostic importance in patients with 
COPD remains poorly described. 
Objective: To characterize the nature of the relationship between BP and heart rate with 
mortality and morbidity in COPD.  
Design: Post-hoc analysis of the associations between baseline BP and heart rate with all-cause 
mortality and cardiovascular events in the SUMMIT trial. 
Setting: A randomized double-blind outcome trial of 16,485 participants enrolled at 1,368 sites 
in 46 countries. 
Participants: Patients with moderate COPD with or at-risk for cardiovascular disease. 
Interventions: Patients were randomized to placebo, a long-acting beta agonist, an inhaled 
corticosteroid, or their combination. 
Main Outcome(s) and Measure(s): All-cause mortality and composite cardiovascular events. 
Results: Participants were 65±8 years, 75% were male, and 47% remained active smokers. 
Baseline BP and heart rate were 133±15/79±9 mmHg and 76±10 /min respectively. All-cause 
mortality increased in relation to high systolic (≥140 mmHg; hazard ratio (HR) 1.27 [95% CI 
1.11-1.45]) or diastolic (>90 mmHg; HR 1.35 [95% CI 1.15-1.59]) BP and low systolic (<115 
mmHg; HR 1.50 [95% CI 1.22-1.83]) or diastolic (<75 mmHg; HR 1.22 [95% CI 1.06-1.40]) 
BP. Higher heart rates (≥80 /min; HR 1.39 [95% CI 1.21-1.60]) and pulse pressures (≥60 mmHg; 
HR 1.16 [95% CI 1.01-1.34]) were linearly-related to increases in all-cause mortality. The risks 
of cardiovascular events followed similar patterns to all-cause mortality. Similar findings were 
observed in subgroups of patients without established cardiovascular disease. 
Conclusions and Relevance: Systolic and diastolic BP levels demonstrated a “U-shaped” 
relationship with all-cause mortality and cardiovascular events in patients with COPD and 
heightened cardiovascular risk. These findings extend the prognostic importance of BP to this 
growing group of patients and raise concerns that both high and low BP may pose health risks.  
 
Trial Registration: ClinicalTrials.gov, number NCT01313676. 
  
Introduction 
High blood pressure (BP) is the leading risk factor for global deaths and disability.1 
Measurement of this simple, yet modifiable, biomarker has proven to be invaluable in the global 
battle against cardiovascular disease.2 Mounting evidence further supports that an elevated heart 
rate is an additional easily-obtained hemodynamic metric independently predictive of all-cause 
as well as cardiovascular mortality.3  
Patients with chronic obstructive pulmonary disease (COPD) die more frequently from 
cardiovascular than respiratory disease.4-6 Over 6% of the United States’ population has been 
told by a health professional that they have COPD,7 and this prevalence appears to be similar in 
the 86 million patients with hypertension.8 Thus, it is likely that over 5 million patients have co-
morbid COPD and hypertension. This is important because a wealth of evidence accrued over 
the past half-century demonstrates that elevated BPs above ideal (<115/75 mm Hg) are 
monotonically (log-linearly) associated with increased cardiovascular events in the general 
population.9,10 However, this relationship is more complex and perhaps non-linear among 
patients with established heart disease.11-13 We therefore wanted to understand the prognostic 
value of BP specifically among individuals with COPD at heightened cardiovascular risk 
because this remains largely undescribed.  
The Study to Understand Mortality and MorbidITy (SUMMIT) was a multi-center 
prospective, double-blind, randomized trial comparing placebo, a long-acting beta agonist 
(LABA), an inhaled corticosteroid (ICS), and their combination in patients with moderate COPD 
with or at risk for cardiovascular disease.14,15 The primary (all-cause mortality) and secondary 
efficacy (composite cardiovascular events) outcomes did not differ between treatment arms.16  
Nevertheless, this large trial with well-adjudicated outcomes provides a unique opportunity to 
explore in detail the nature of the relationships between BP and heart rate with all-cause 
mortality and cardiovascular events in a contemporary population of high-risk individuals with 
COPD.  
 
Methods 
 SUMMIT included 16,485 participants enrolled across 1,368 centers in 46 counties with 
an average follow-up period for on-treatment cardiovascular outcomes of 1.7 years and on and 
post-treatment mortality of 1.9 years. The protocol, CONSORT diagram, and trial outcomes have 
been described in detail previously.14,15 In brief, eligible participants included current or former 
smokers (≥10-pack-years) between the ages of 40 and 80 years, with a history of COPD and a 
post-bronchodilator FEV1 ≥50 and ≤70% of the predicted value, a ratio of post-bronchodilator 
FEV1 to forced vital capacity (FVC) ≤0.70, and a score ≥2 on the modified Medical Research 
Council dyspnea scale. Patients were required to be at increased cardiovascular risk (defined as 
being ≥60 years plus receiving medications for ≥2 of the following: hypercholesterolemia, 
hypertension, diabetes mellitus, or peripheral vascular disease) or have established disease 
(coronary artery disease, peripheral arterial disease, prior stroke or MI, or diabetes mellitus with 
target organ disease). The on-treatment composite secondary cardiovascular outcome included 
cardiovascular death, myocardial infarction (MI), stroke, unstable angina, and transient ischemic 
attack (TIA). 
 
 
 
Hemodynamic Measurements 
Study sites were instructed to perform vital signs prior to spirometry at all study visits 
and to measure systolic and diastolic BP as well as heart rate in the seated position after 5 min of 
rest. The BP and heart rate values obtained at the baseline visit (study visit #2) after the 
screening visit were used for these post-hoc analyses. The sphygmomanometer equipment and 
study staff that measured BP were consistent with the standard clinical practices of the 
investigators at each location. 
 
Statistical Methods 
 The rates of all-cause mortality per 100 subject years were calculated as (100 x number 
of deaths)/total on- and post-treatment follow-up. The rates of on-treatment cardiovascular 
composite events were calculated as (100 x number of events)/total on-treatment follow-up. Both 
rates were calculated for 5 mmHg categories of systolic and diastolic BP and for each 5 beat/min 
category of heart rate. These results and the 95% confidence intervals (CIs)17 were calculated 
across the range of baseline BP and heart rate values.  
We calculated the hazard ratios (HR) and 95% CIs using Cox regression adjusted for the 
covariates of randomised treatment, age, sex, body-mass index (BMI), smoking habit and beta 
blocker use. The HRs were calculated for the time to death (or first cardiovascular endpoint) 
compared across 3 ranges of BP and heart rate values. These ranges for systolic (<115, ≥115 - 
<140, ≥140 mm Hg), diastolic BP (<75, ≥75 - <90, ≥90 mm Hg), and pulse pressure (<50, ≥50 - 
<60, ≥60 mm Hg) were selected based upon their clinical relevance and reasonable distribution 
within the population values. Similar models were calculated for heart rate ranges (<70, ≥70 - 
<80, ≥ 80 beats per minute). 
Results 
Demographic and Hemodynamic Characteristics 
The average age of study participants was 65±8 years, 75% were male, and 47% 
remained active smokers. The mean body-mass index was 28±6 kg/m2. Most individuals were 
white (81%), while 17% and 2% were Asian or another race, respectively. By our study 
definition, 71% of participants had cardiovascular disease. Excluding diabetes plus target organ 
disease from this definition, 66% of patients had “overt” disease (e.g., prior MI). As previously 
reported,16 the population of patients were well-treated with contemporary medications with 
more than half on statins (64-66%) and anti-platelet (51-53%) therapies. 
While there was a large overall range, the average baseline BP among participants was 
within the controlled category (<140/90 mm Hg; Table 1). Given the age and co-morbidities of 
the participants, nearly 90% were receiving some type of antihypertensive medication with the 
most common being a renin-angiotensin system inhibitor or antagonist (Table 2). 
 
Baseline Hemodynamic Parameters, All-Cause Mortality and Cardiovascular Risk 
 Table 3 shows the risks for all-cause mortality and cardiovascular composite events in 
association with BP and heart rate levels measured at baseline among SUMMIT participants. 
Compared with the middle range, the risks of an event were higher in those with systolic and 
diastolic BP levels in either the higher or lower ranges (Figures S1, S2, S3 and S4; online 
supplement). The HRs for mortality for systolic BP were: high range vs middle range HR=1.27, 
low range vs middle range HR=1.50. The HRs for mortality for diastolic BP were: high range vs 
middle range HR=1.35, low range vs middle range HR=1.22 (Table 3). Conversely, there 
appeared to be an increasing risk of death with increasing heart rate only (Figure S5) (high range 
vs middle range HR=1.39, low range vs middle range HR=0.83, Table 3), with a similar trend 
for cardiovascular events (Figure S6). Like heart rate, only high (but not low) pulse pressure was 
associated with increased risk of an event (Figures S7 and S8) (for mortality, high range vs 
middle range HR=1.17, Table 3).  
 
Relationships between BP and heart rate with Morbidity and Cardiovascular Events 
 The associations between all-cause mortality and systolic and diastolic BP across the 
entire range of baseline study values were consistent with a generally “U”-shaped relationship: 
progressively higher and lower values outside optimal ranges being associated with increasing 
mortality rates (Figures 1A and 1B).  The nadir of risk visually appears to be among patients 
with a BP from 125-135/75-90 mm Hg. There appears to be more of a linear relationship 
between heart rate and mortality (particularly disregarding the extreme outliers with heart rates 
<45 beats/minute, (Figure 2A). However, there appears to be a less clear relationship between 
pulse pressure and mortality (Figure 2B).  When similarly plotted, the risks associated with 
cardiovascular events followed a similar pattern (Figures S9-S12). In models including 
additional covariates (e.g., other anti-hypertensive medications), there were no consistent 
significant changes in the outcomes. 
Baseline Hemodynamic Characteristics, All-Cause Mortality and Cardiovascular Risk by Patient 
History 
We investigated the effects of hemodynamic parameters on the risk of events in the 
subgroups of patients with and without previous coronary heart disease and in the subgroups of 
patients with a history of cardiovascular disease (per trial definition) and those only at 
heightened cardiovascular risk (i.e., no overt disease) (Tables S1 and S2). In general, the 
patterns of outcomes were similar in each group to the main findings. The higher risks of 
mortality and cardiovascular events due to low systolic and diastolic BP were also observed in 
patients at heightened risk but without overt disease. This supports that this “U-shaped” 
relationship was not confined only to this with a prior cardiovacular event or underlying disease.  
 
Discussion 
 Elevated BP levels above ideal (>115/75 mm Hg) are monotonically linked to increased 
morbidity and mortality in the general population.9,10 However, the prognostic value of high BP 
specifically among individuals with COPD remains poorly described. Here, we report for the 
first time that both high and low BPs are associated with increased all-cause mortality and 
cardiovascular events in patients with COPD at high risk for cardiovascular events or with 
cardiovascular disease. This relationship was observed even among patients without a history of 
a prior cardiovascular event or established disease. In contrast, only a higher heart rate and pulse 
pressure were associated with increases in risks. These findings raise warnings that health care 
providers may need to be concerned about a worse prognosis in patients with COPD both with 
high as well as low systolic and diastolic BPs. 
Outside the context of COPD, the relationship between hemodynamic measures and 
mortality has been determined in extremely large datasets, yielding high confidence in the 
results. In an analysis of over 1 million people without vascular disease at the initiation of 
longitudinal study, BP was associated with outcomes in a monotonic log-linear fashion.9 A more 
recent analysis confirmed these findings in 1.25 million people initially free of cardiovascular 
disease.10  Conversely, in patients with coronary heart disease, a “U-shaped” relationship has 
been variably observed, as exemplified by a recent global observational study of over 22,000 
patients.11  Similarly, systolic and diastolic BP were recently found to have U-shaped 
relationships with all-cause mortality among participants at high risk for cardiovascular events in 
the TRANSCEND and ONTARGET trials.18  Yet, earlier studies have not consistently 
confirmed these findings, particularly after adjusting for confounding factors.12 The topic of a 
“U-shaped” or “J-curve” relationship between BP and cardiovascular outcomes in patients with 
coronary heart disease has generated significant controversy over the years.12,13 The main 
concerns pertain to the clinical implications. Are low BPs a marker of poor underlying health 
(i.e., “reverse-causation”) or do treatment-induced reductions below a threshold (particularly of 
diastolic BP) lead to decreased coronary perfusion? Are additional vascular territories such as 
cerebral perfusion also impacted? Do these risks only pertain to patients with pre-existing 
coronary atherosclerosis?  What is the optimal BP level to target with antihypertensive treatment 
in order to reduced cardiovascular risk? Despite decades of research varying opinions persist12,13. 
The debate has intensified recently following the SPRINT study19 and a network meta-analysis 
(both suggesting that an optimal systolic BP level is 120-125 mm Hg).20  Our observational 
findings cannot specifically address these issues. However, they do raise concerns that these 
questions may also apply to high-risk patients with COPD. 
Despite availability of robust data on relationships between hemodynamic measures and 
mortality, there are scant data in the population of patients with COPD. Consistent with our 
findings and those in other populations,3 resting heart rate has been reported in the past to predict 
mortality in COPD21 and cardiovascular mortality in coronary artery disease.22 A fast heart rate 
may be a risk marker of autonomic imbalance heightening the potential for arrhythmias or 
sudden death, and it may directly promote myocardial ischemia or damage. Moreover, faster 
heart rates might be an indicator of poor fitness or severity of illness. It is important to note, 
however, that there remains no trial evidence that pharmacologically lowering heart rate (e.g. 
beta blockade) directly translates into a reduction in risk in patients with COPD. In a clinical 
setting in which higher heart rate is associated with worse outcomes, ivabradine lowered heart 
rate in a trial of patients with stable coronary artery disease and left ventricular systolic 
dysfunction, but did not improve mortality.23 Regardless, we confirm here in high-risk patients 
with COPD that increases in heart rates are associated not only with mortality, but also excess 
cardiovascular events. 
Patients 45 years of age and older, and meeting the Global Initiative for Obstructive Lung 
Disease (GOLD) criteria for COPD in the Atherosclerosis Risk in Communities Study (ARIC) 
and the Cardiovascular Health Study (CHS) were studied by Mannino et al.24 They found an 
increased risk of hospitalization and mortality in patients with COPD and hypertension—
considered as a dichotomous variable—compared to patients with impaired lung function. Our 
study is more comprehensive in several respects, including our assessment of hemodynamic 
variables as continuous measures, evaluating the impact of both high and low levels, and our 
specific analyses of systolic BP, diastolic BP, pulse pressure, and heart rate. Perhaps owing to 
concern for the effect of specific drug classes (e.g., beta blockers), some prior work has been 
done describing the relationships between specific antihypertensive drugs and cardiovascular 
outcomes in COPD. Indeed, a recent meta-analysis supports the safety and overall cardiovascular 
protection of beta blockade in patients with COPD.25 We similarly observed no evidence of harm 
related to beta blocker usage in the SUMMIT trial (manuscript in review). Herrin and colleagues 
reported in a retrospective analysis that two-drug antihypertensive combinations including a 
thiazide diuretic were more effective for preventing heart failure hospitalizations in patients with 
COPD.26 The paucity of overall evidence and lack of prospective outcome trials means that the 
optimal BP target and ideal antihypertensive regimen for patients with COPD must remain a 
matter of expert opinion. 
 There are several limitations to note. Foremost, this was a post-hoc observational study 
and the findings must therefore be considered hypothesis-generating. The methodology for 
measurement of BP in the SUMMIT trial was not governed by strict protocols and multiple 
aspects pertaining to its accuracy likely varied across the 1,368 sites. We only evaluated the 
outcomes based upon BP levels at the start of the trial and not time-averaged values. These facts 
would tend to bias observational analyses toward the null. Nonetheless, significant health 
associations with a single BP reading were still detected. More rigorous standardization as well 
as multiple determinations of BP (or ambulatory BP monitoring) would likely have yielded an 
even more robust signal. We believe our findings therefore highlight the strength of the linkage 
between BP with health risks in patients with COPD. Our findings do not directly impugn low 
BP as being harmful per se. We cannot exclude that it may simply be a marker of poor health or 
“reverse-causation.” Regardless, our study represents the first large-scale evaluation of the nature 
of the relationship between BP and all-cause mortality and cardiovascular events (which were 
well-adjudicated in a clinical trial setting) specifically in a population of patients with COPD.  
 
 
 Conclusions 
 Both high and low BPs are associated with increased mortality and excess cardiovascular 
events, whereas faster heart rates are linked to health risks, in individuals with COPD at 
heightened cardiovascular risk. Further studies are warranted to confirm our findings and 
investigate the clinical implications as well as the benefits, optimal anti-hypertensive strategies, 
and BP treatment goals in this important and growing global population of patients.  
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Table 1.  Participant Hemodynamic Measures. 
 n Mean (SD) Minimum  Maximum 
Systolic BP (mm Hg) 16482 133 (15) 70 220 
Diastolic BP (mm Hg) 16482 79 (9) 40 140 
Pulse Pressure (mm Hg) 16482 54 (12) 13 120 
Heart Rate (beats/min) 16481 76 (10) 40 147 
 
 
 
Table 2. Anti-Hypertensive Medications at Study Entry. 
 Number of participants Percentage 
Number of Medications   
None 1,740 11% 
 1 5,761 35% 
 2 4,777 29% 
 ≥3 4,207 26% 
Medication Class   
 Beta blockers 5,159 31% 
 Calcium channel blockers 5,690 35% 
 Diuretics 5,449 33% 
 ACEi* or ARB† 10,981 67% 
 Other 763  5% 
*ACEi, angiotensin-converting enzyme inhibitor; †ARB, angiotensin receptor blocker 
  
Table 3. Study Events by Baseline Blood Pressures and Heart Rates. 
   All-Cause Mortality CVD Event 
 Hazard 
ratio  
95% CI Hazard 
ratio 
95% CI 
Systolic blood pressure (HR vs. 
≥115 to <140 mm Hg; n=9,144) 
    
 <115 mm Hg (n=1,394) 1.50 1.22-1.83 1.30 1.00-1.69 
 ≥140 mm Hg (n=5,944) 1.27 1.11-1.45 1.19 1.01-1.39 
Diastolic blood pressure (HR vs. 
≥75 to <90 mm Hg; n=8,875) 
    
 <75 mm Hg (n=4,565) 1.22 1.06-1.40 1.37 1.15-1.63 
 ≥90 mm Hg (n=3,042) 1.35 1.15-1.95 1.53 1.26-1.85 
Pulse Pressure (HR vs. ≥50 to <60 
mm Hg; n=5,899) 
    
 <50 mm Hg (n=4,993) 1.03 0.88-1.21 1.09 0.90-1.32 
 ≥60 mm Hg (n=5,590) 1.16 1.01-1.34 1.21 1.01-1.45 
Heart Rate (HR vs. ≥70 to <80 
beats/min; n=6,658) 
    
 < 70 beats/min (n=3,896) 0.83 0.70-0.99 0.93 0.76-1.13 
 ≥80 beats/min (n=5,927) 1.39 1.21-1.60 1.22 1.02-1.44 
CI, confidence interval; CVD, cardiovascular disease (secondary composite outcome).  
*The hazard ratio represents the risks compared to the middle ranges of values for each 
parameter 
  
Figure Legends. 
Figure 1A. All-cause Mortality and Systolic Blood Pressure  
Rate of death per 100 subject years is shown, grouped in 5 mmHg categories according to 
baseline systolic blood pressure. 
Note: A yellow triangle represents categories where there were zero deaths, so a rate could not 
be calculated. 
Figure 1B. All-cause Mortality and Diastolic Blood Pressure  
Rate of death per 100 subject years is shown, grouped in 5 mmHg categories according to 
baseline diastolic blood pressure. 
Note: A yellow triangle represents categories where there were zero deaths, so a rate could not 
be calculated. 
Figure 2A. All-cause Mortality and Heart Rate  
Rate of death per 100 subject years is shown, grouped in 5 beats/minute categories according to 
baseline heart rate. 
Note: A yellow triangle represents categories where there were zero deaths, so a rate could not 
be calculated. 
Figure 2B. All-cause Mortality and Pulse Pressure  
Rate of death per 100 subject years is shown, grouped in 5 mmHg categories according to 
baseline pulse pressure. 
Note: A yellow triangle represents categories where there were zero deaths, so a rate could not 
be calculated.
Figure 1. 
 
  
Figure 2. 
 
Supplemental Data 
Table S1. Study Events by Baseline Blood Pressures and Heart Rates – Split by Cardiovascular History and 
Risk at Screening 
   All-Cause Mortality CVD Event 
 HR*  95% CI HR  95% CI 
Age 40-60 with CV Disease 
Systolic blood pressure (HR vs. ≥115 to <140 mm Hg; n=2,028) 
 ≥140 mm Hg (n=1,190) 1.30 0.92-1.86 1.38 0.94-2.04 
 <115 mm Hg (n=317) 1.26 0.72-2.20 1.12 0.55-2.28 
Diastolic blood pressure (HR vs. ≥75 to <90 mm Hg; n=1,962) 
 ≥90 mm Hg (n=853) 1.34 0.91-1.97 1.67 1.09-2.54 
 <75 mm Hg (n=720) 1.08 0.70-1.66 1.26 0.77-2.06 
Pulse Pressure (HR vs. ≥50 to <60 mm Hg; n=1,310) 
 ≥60 mm Hg (n=901) 1.34 0.90-2.00 1.10 0.70-1.72 
 <50 mm Hg (n=1,324) 0.87 0.58-1.30 0.84 0.54-1.31 
Heart Rate (HR vs. ≥70 to <80 beats/min; n=1,514) 
 ≥80 beats/min (n=1,294) 1.63 1.13-2.35 1.22 0.82-1.81 
 < 70 beats/min (n=726) 0.95 0.57-1.58 0.58 0.32-1.05 
Age 60-80 with CV Disease 
Systolic blood pressure (HR vs. ≥115 to <140 mm Hg; n=4,431) 
 ≥140 mm Hg (n=2,962) 1.27 1.08-1.50 1.13 0.93-1.37 
 <115 mm Hg (n=732) 1.44 1.12-1.85 1.29 0.95-1.76 
Diastolic blood pressure (HR vs. ≥75 to <90 mm Hg; n=4,279) 
 ≥90 mm Hg (n=1,339) 1.41 1.14-1.73 1.46 1.15-1.86 
 <75 mm Hg (n=2,507) 1.18 0.99-1.40 1.32 1.07-1.62 
Pulse Pressure (HR vs. ≥50 to <60 mm Hg; n=2,866) 
 ≥60 mm Hg (n=2,959) 1.04 0.87-1.25 1.22 0.98-1.51 
 <50 mm Hg (n=2,300) 1.01 0.83-1.23 1.07 0.84-1.35 
Heart Rate (HR vs. ≥70 to <80 beats/min; n=3,215) 
 ≥80 beats/min (n=2,741) 1.36 1.14=1.62 1.29 1.05-1.60 
 < 70 beats/min (n=2,169) 0.78 0.63-0.97 0.96 0.75-1.21 
Age 60-80 with CV Risk but not Disease 
Systolic blood pressure (HR vs. ≥115 to <140 mm Hg; n=2,600) 
 ≥140 mm Hg (n=1,710) 1.23 0.94-1.62 1.15 0.77-1.71 
 <115 mm Hg (n=330) 1.69 1.10-2.59 1.21 0.57-2.54 
Diastolic blood pressure (HR vs. ≥75 to <90 mm Hg; n=2,539) 
 ≥90 mm Hg (n=803) 1.20 0.85-1.71 1.52 0.92-2.51 
 <75 mm Hg (n=1,298) 1.31 0.98-1.74 1.50 0.97-2.32 
Pulse Pressure (HR vs. ≥50 to <60 mm Hg; n=1,662) 
 ≥60 mm Hg (n=1,661) 1.49 1.09-2.02 1.36 0.85-2.17 
 <50 mm Hg (n=1,317) 1.27 0.91-1.78 1.60 0.98-2.61 
Heart Rate (HR vs. ≥70 to <80 beats/min; n=1,859) 
 ≥80 beats/min (n=1,815) 1.37 1.03-1.82 1.02 0.67-1.55 
 < 70 beats/min (n=966) 0.81 0.55-1.20 0.88 0.52-1.50 
HR, hazard ratio; CI, confidence interval; CVD, cardiovascular disease (secondary composite outcome).  
*The HR represents the risks compared to the middle ranges of values for each parameter 
183 patients did not meet the CV risk/disease inclusion criteria, so are not included in this table. 
  
Table S2. Study Events by Baseline Blood Pressures and Heart Rates – Split by Previous MI/CABG/PCI 
   All-Cause Mortality CVD Event 
 HR*  95% CI HR  95% CI 
Previous MI/CABG/PCI 
Systolic blood pressure (HR vs. ≥115 to <140 mm Hg; n=1,908) 
 ≥140 mm Hg (n=1,090) 1.29 0.99-1.68 1.31 1.00-1.74 
 <115 mm Hg (n=436) 1.09 0.74-1.60 1.07 0.71-1.62 
Diastolic blood pressure (HR vs. ≥75 to <90 mm Hg; n=1,721) 
 ≥90 mm Hg (n=490) 1.15 0.80-1.65 1.37 0.95-1.99 
 <75 mm Hg (n=1,224) 0.94 0.72-1.23 1.29 0.97-1.71 
Pulse Pressure (HR vs. ≥50 to <60 mm Hg; n=1,140) 
 ≥60 mm Hg (n=1,174) 0.95 0.72-1.27 1.20 0.89-1.63 
 <50 mm Hg (n=1,121) 0.86 0.63-1.17 0.81 0.58-1.14 
Heart Rate (HR vs. ≥70 to <80 beats/min; n=1,346) 
 ≥80 beats/min (n=949) 1.51 1.13-2.01 0.96 0.70-1.31 
 < 70 beats/min (n=1,139) 0.91 0.67-1.24 0.70 0.51-0.96 
No Previous MI/CABG/PCI 
Systolic blood pressure (HR vs. ≥115 to <140 mm Hg; n=7,235) 
 ≥140 mm Hg (n=4,854) 1.28 1.10-1.48 1.17 0.96-1.42 
 <115 mm Hg (n=958) 1.68 1.33-2.13 1.36 0.97-1.91 
Diastolic blood pressure (HR vs. ≥75 to <90 mm Hg; n=7,154) 
 ≥90 mm Hg (n=2,552) 1.42 1.19-1.71 1.63 1.30-2.05 
 <75 mm Hg (n=3,341) 1.32 1.12-1.55 1.32 1.05-1.64 
Pulse Pressure (HR vs. ≥50 to <60 mm Hg; n=4,759) 
 ≥60 mm Hg (n=4,416) 1.25 1.05-1.47 1.21 0.97-1.51 
 <50 mm Hg (n=3,872) 1.09 0.91-1.31 1.21 0.96-1.53 
Heart Rate (HR vs. ≥70 to <80 beats/min; n=5,312) 
 ≥80 beats/min (n=4,978) 1.37 1.18-1.60 1.41 1.15-1.74 
 < 70 beats/min (n=2,757) 0.78 0.63-0.97 1.04 0.80-1.35 
HR, hazard ratio; CI, confidence interval; CVD, cardiovascular disease (secondary composite outcome).  
*The HR represents the risks compared to the middle ranges of values for each parameter 
Supplementary Figure Legends. 
Figure S1. All-cause Mortality and Systolic Blood Pressure Ranges 
Kaplan Meier plot of time to death by systolic blood pressure ranges. 
Figure S2. All-cause Mortality and Diastolic Blood Pressure Ranges 
Kaplan Meier plot of time to death by diastolic blood pressure ranges. 
Figure S3. Cardiovascular Composite Events and Systolic Blood Pressure Ranges 
Kaplan Meier plot of time to death by systolic blood pressure ranges. 
Figure S4. Cardiovascular Composite Events and Diastolic Blood Pressure Ranges 
Kaplan Meier plot of time to death by diastolic blood pressure ranges. 
Figure S5. All-cause Mortality and Heart Rate Ranges 
Kaplan Meier plot of time to death by heart rate ranges. 
Figure S6. Cardiovascular Composite Events and Heart Rate Ranges 
Kaplan Meier plot of time to death by heart rate ranges. 
Figure S7. All-cause Mortality and Pulse Pressure Ranges 
Kaplan Meier plot of time to death by pulse pressure ranges. 
Figure S8. Cardiovascular Composite Events and Pulse Pressure Ranges 
Kaplan Meier plot of time to death by pulse pressure ranges. 
Figure S9. Cardiovascular Composite Events and Systolic Blood Pressure  
Rate of CV events per 100 subject years is shown, grouped in 5 mm Hg categories according to baseline systolic blood pressure. 
Note: A yellow triangle represents categories where there were zero deaths, so a rate could not be calculated. 
Figure S10. Cardiovascular Composite Events and Diastolic Blood Pressure  
Rate of CV events per 100 subject years is shown, grouped in 5 mm Hg categories according to baseline diastolic blood pressure.  
Note: A yellow triangle represents categories where there were zero deaths, so a rate could not be calculated. 
Figure S11. Cardiovascular Composite Events and Pulse Pressure  
Rate of CV events per 100 subject years is shown, grouped in 5 mm Hg categories according to baseline pulse pressure.  
Note: A yellow triangle represents categories where there were zero deaths, so a rate could not be calculated. 
Figure S12. Cardiovascular Composite Events and Heart Rate  
Rate of CV events per 100 subject years is shown, grouped in 5 beats/minute categories according to baseline heart rate. 
Note: A yellow triangle represents categories where there were zero deaths, so a rate could not be calculated. 
  
Figure S1 
 
  
Figure S2 
 
 
Figure S3 
   
Figure S4 
 
 
Figure S5 
 
 Figure S6 
 
 Figure S7 
 
 Figure S8 
 

Figure S9 
 
  
Figure S10 
 
  
Figure S11 
 
  
Figure S12 
 
 
